The main point is the confirmation of the statistically significant eGFR benefits and the reduction in proteinuria, as revealed earlier. We point to further support for a potentially positive disease-modifying effect by Tarpeyo (Nefecon) as suggested by several established biomarkers. The study results support our base case (SEK 295), which rests on the potency of a targeted locally acting immunosurpressing product that also reduces inflammation. We also point to the benefit of providing more detailed results ahead of the critical PDUFA date on 20 December. 2023.